Zentalis Pharma (ZNTL) - חוב להון עצמי

Zentalis Pharmaceuticals (ZNTL) operations are constrained by the risks of disrupted logistics chains and the complexities of protecting intellectual property amid global instability. This price chart visualizes these processes, while the total debt-to-equity ratio stands at 0.25. The business relies on long-term demand for oncology therapy, although high R&D costs are temporarily curbing profit growth due to significant fixed expenses.

The total debt-to-equity ratio measures the proportion of borrowed liabilities relative to equity, determining the issuer's financial stability and default risk. By analyzing the current debt-to-equity ratio, an investor can assess how effectively Zentalis Pharmaceuticals (ZNTL) finances costly small-molecule clinical trials and strategic alliances with biolabs without creating an excessive debt burden on the balance sheet structure.